aTyr Pharma Announces Third Quarter 2026 Results and Corporate Update

aTyr Pharma reported no revenue in the third quarter of 2026, compared with $190,000 a year earlier, and a net loss of $18.3 million. It ended the quarter with $50.3 million in cash and investments, which it expects to fund operations into late 2028. The company said it aligned with the FDA on the protocol for a global Phase 3 trial of efzofitimod for chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, and is prioritizing partnerships or licensing arrangements to advance the study.